Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) (NIPPV)

3. desember 2014 oppdatert av: McMaster University

Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants

The machines and oxygen used to help very premature babies breathe can have side-effects, such as bronchopulmonary dysplasia (BPD). Infants with BPD get more complications (a higher death rate, a longer time in intensive care and on assisted ventilation, more hospital readmissions in the first year of life, and more learning problems) than infants who do not develop BPD. Doctors try to remove the tube in the wind-pipe that links the baby to the breathing machine as soon as possible. However, small babies get tired, and still require help to breathe. One of the standard and common techniques to help them breathe without a tube in the wind-pipe is to use simple pressure support, nasal continuous positive airway pressure or nCPAP. This supports breathing a little, but it is often not enough to prevent the need to go back on the breathing machine.

Nasal intermittent positive pressure ventilation (NIPPV) is similar to nCPAP, but also gives some breaths, or extra support, to babies through a small tube in the nose. NIPPV is safe and effective, and already in use as an alternate "standard" therapy.

The main research question: After being weaned from the breathing machine, is NIPPV better than nCPAP in preventing BPD in premature babies weighing 999 grams or less at birth?

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

The immature lung of extremely low birth weight (ELBW, < 1000 g) infants is easily damaged by the placement of an endotracheal tube to deliver mechanical ventilation and oxygen. This and the total time of mechanical ventilation contributes to bronchopulmonary dysplasia (BPD). Infants with BPD have an increased risk of later death or neuro-impairment. With the increasing survival of ELBW infants in the NICU, there has been a proportionate increase in the number of infants surviving with BPD.

Following invasive ventilation via an endotracheal tube (ETT), extubation to nasal Continuous Positive Airway Pressure (nCPAP)ventilation is the standard approach. Currently, 40% of infants who are extubated and given nCPAP support fail, and require re-intubation. Previous work suggests that a less invasive respiratory support such as Nasal Intermittent Positive Pressure Ventilation (NIPPV), without an endotracheal tube is less injurious to the lung. NIPPV may thereby reduce the duration of invasive ventilator support, and aid successful early extubation. We hypothesize that the use of NIPPV leads to a higher rate of survival without BPD than standard therapy with nCPAP.

This randomized clinical trial is appropriately powered to compare NIPPV with nCPAP to detect effects on clinically relevant long-term outcomes, such as death and BPD at 36 weeks. This is a multi-national, randomized, open clinical trial of two different standard methods of providing non-invasive respiratory support to 1000 extremely preterm infants weighing less than 1000 grams at birth.

Studietype

Intervensjonell

Registrering (Faktiske)

1011

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Rocourt, Belgia, B-4000
        • CHC St. Vincent
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • Winnipeg Health Sciences Centre
      • Winnipeg, Manitoba, Canada, R3E 0L8
        • St. Boniface General Hospital/University of Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • IWK Health Centre
    • Ontario
      • Hamilton, Ontario, Canada, L8S 4J9
        • McMaster University
      • Ottawa, Ontario, Canada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital General Campus
      • Toronto, Ontario, Canada
        • Hospital for Sick Children
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • Royal University Hospital
    • District of Columbia
      • Washington, District of Columbia, Forente stater, 20037
        • The George Washington University Hospital
      • Washington, District of Columbia, Forente stater, 20007
        • Georgetown University Children's Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Beth Israel Deaconess Medical Center (Bidmc)
      • Boston, Massachusetts, Forente stater, 02111
        • Tufts University Medical Center
    • New Jersey
      • Voorhees, New Jersey, Forente stater, 08043
        • Virtua West Jersey Hospital
    • New York
      • Brooklyn, New York, Forente stater, 11203
        • Kings County Hospital
      • Brooklyn, New York, Forente stater, 11023
        • SUNY Downstate Medical Center
      • Brooklyn, New York, Forente stater, 11355
        • New York Hospital Queens
      • Jamaica, New York, Forente stater, 11432
        • Queens Hospital Center
      • New York, New York, Forente stater, 11212
        • Brookdale University Hospital & Medical Center
      • Stony Brook, New York, Forente stater, 11794-8111
        • Stony Brook University Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Children's Hospital of Philadelphia
      • Philadelphia, Pennsylvania, Forente stater, 19035
        • Pennsylvania Hospital/U. of Pennsylvania
    • Utah
      • Salt Lake City, Utah, Forente stater, 84158-1289
        • University of Utah
      • Dublin, Irland
        • National Maternity Hospital
      • Dublin, Irland
        • Coombe Women's Hospital
    • Cork
      • Wilton, Cork, Irland
        • Cork University Maternity Hospital
      • Groningen, Nederland, 9700 RB
        • University Medical Center Groningen/Beatrix Children's Hosp
      • Zwolle, Nederland, 8000 GK
        • Princess Amalia Dept of Pediatrics, Isala Clinics
      • Doha, Qatar
        • Hamad Medical Corporation
      • Singapore, Singapore, 229899
        • KK Women's and Children's Hospital
      • Leicester, Storbritannia, LE1 6TP
        • University of Leicester
      • London, Storbritannia, W2 1NY
        • St. Mary's Hospital
    • Northern Ireland
      • Belfast, Northern Ireland, Storbritannia, BT12 6BB
        • Royal Maternity Hospital
      • Stockholm, Sverige, S-171 76
        • Karolinska University Hospital/Astrid Lingrenn's Children's Hospital
      • Feldkirch, Østerrike, 6800
        • LKH Feldkirch

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 4 uker (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Birth weight <1000 gm
  • Gestational age <30 completed weeks
  • Intention to manage the infant with non-invasive respiratory support (i.e. no endotracheal tube), where either:

    • the infant is within the first 7 days of life and has never been intubated or has received less than 24 hours of total cumulative intubated respiratory support;
    • the infant is within the first 28 days of life, has been managed with intubated respiratory support for 24 hours or more and is a candidate for extubation followed by non-invasive respiratory support.

Exclusion Criteria:

  • Considered non-viable by clinician (decision not to administer effective therapies)
  • Life-threatening congenital abnormalities including congenital heart disease (excluding patent ductus arteriosis)
  • Infants known to require surgical treatment
  • Abnormalities of the upper and lower airways
  • Neuromuscular disorders
  • Infants who are >28 days old and continue to require mechanical ventilation with an endotracheal tube

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: A
Non-invasive respiratory support via nasal intermittent positive pressure ventilation
Deliver non-invasive respiratory support via ventilator with NIPPV device
Aktiv komparator: B
Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
Deliver non-invasive respiratory support via ventilator with nCPAP device

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Composite of survival to 36 weeks gestational age, free of moderate-severe bronchopulmonary dysplasia
Tidsramme: 36 weeks gestational age
36 weeks gestational age

Sekundære resultatmål

Resultatmål
Tidsramme
Alle forårsaker dødelighet ved 36 ukers svangerskapsalder
Tidsramme: 36 ukers svangerskapsalder
36 ukers svangerskapsalder
retinopati av prematuritet
Tidsramme: slippe hjem
slippe hjem
All cause mortality before first discharge home
Tidsramme: first discharge home
first discharge home
ultrasonographic evidence of brain injury
Tidsramme: 36 weeks gestional age
36 weeks gestional age
necrotizing enterocolitis
Tidsramme: 36 weeks gestational age
36 weeks gestational age
growth
Tidsramme: discharge home
discharge home
time to establish full feeds
Tidsramme: discharge home
discharge home
nosocomial infections
Tidsramme: discharge home
discharge home
need for re-intubation
Tidsramme: 36 weeks gestational age
36 weeks gestational age
time on supplemental oxygen
Tidsramme: discharge home
discharge home
duration of positive pressure respiratory support
Tidsramme: discharge home
discharge home
comparison of synchronized and non-synchronized NIPPV
Tidsramme: discharge home
discharge home
bronchopulmonary dysplasia
Tidsramme: 36 weeks gestational age
36 weeks gestational age
air leak syndromes
Tidsramme: 36 weeks gestational age
36 weeks gestational age
nasal trauma
Tidsramme: discharge home
discharge home

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Haresh Kirpalani, MD, MSc, Hamilton Health Sciences Corporation
  • Studieleder: Brigitte Lemyre, MD, Children's Hospital of Eastern Ontario
  • Studieleder: Aaron Chiu, MD, St. Boniface Hospital
  • Studieleder: David Millar, MD, Royal Maternity Hospital, Belfast
  • Studieleder: Robin S Roberts, MTech, Hamilton Health Sciences/McMaster University
  • Studieleder: Bradley Yoder, MD, University of Utah
  • Studieleder: Peter H Dijk, MD, PhD, University Medical Centrum Groningen

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. april 2007

Primær fullføring (Faktiske)

1. august 2011

Studiet fullført (Faktiske)

1. desember 2011

Datoer for studieregistrering

Først innsendt

7. februar 2007

Først innsendt som oppfylte QC-kriteriene

8. februar 2007

Først lagt ut (Anslag)

9. februar 2007

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

5. desember 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. desember 2014

Sist bekreftet

1. desember 2014

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere